The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Research

• Publication date

  2010-01-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-09-2951PMID 20068168
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.

  2009cited by this paper
• TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.

  2009cited by this paper
• Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.

  2008cited by this paper
• Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

  2008cited by this paper
• Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line

  2007cited by this paper
• Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.

  2007cited by this paper
• Treatment of pituitary tumors

  2007cited by this paper
• Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway

  2006cited by this paper
• Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression.

  2006cited by this paper
• mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

  2006cited by this paper
• S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt.

  2006cited by this paper
• Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade

  2005cited by this paper
• mTOR-targeted therapy of cancer with rapamycin derivatives.

  2005cited by this paper
• Non-functioning pituitary adenomas.

  2005cited by this paper
• Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.

  2005cited by this paper
• Enhanced protein kinase B/Akt signalling in pituitary tumours.

  2005cited by this paper
• Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

  2005cited by this paper
• Medical Therapy of Gonadotropin-Producing and Nonfunctioning Pituitary Adenomas

  2004cited by this paper
• mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

  2004cited by this paper
• Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

  2004cited by this paper
• Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk

  2003cited by this paper
• Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression

  2003cited by this paper
• Rapamycins: Mechanisms of Action and Cellular Resistance

  2003cited by this paper
• Somatostatin analogs in the diagnosis and treatment of cancer.

  2002cited by this paper
• Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells.

  2001cited by this paper
• Phosphoinositide-regulated kinases and phosphoinositide phosphatases.

  2001cited by this paper
• Retinoic acid prevents experimental Cushing syndrome.

  2001cited by this paper
• Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

  2001cited by this paper
• The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas.

  2000cited by this paper
• A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1.

  2000cited by this paper
• The Pezcoller lecture: cancer cell cycles revisited.

  2000cited by this paper
• Phosphorylation of Insulin Receptor Substrate-1 (IRS-1) by Protein Kinase B Positively Regulates IRS-1 Function*

  1999cited by this paper
• Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells.

  1999cited by this paper
• sst2 Somatostatin Receptor Mediates Cell Cycle Arrest and Induction of p27 Kip1

  1999cited by this paper
• Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro.

  1999cited by this paper
• Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability*

  1998cited by this paper
• The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal.

  1997cited by this paper
• Role of Translocation in the Activation and Function of Protein Kinase B*

  1997cited by this paper
• Transforming growth factor-beta and p27 expression in pituitary cells.

  1996cited by this paper
• Phosphorylation of Insulin Receptor Substrate-1 on Multiple Serine Residues, 612, 632, 662, and 731, Modulates Insulin Action (*)

  1996cited by this paper
• Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells.

  1995cited by this paper
• Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block.

  1995cited by this paper
• Identification by mutation of the tyrosine residues in the insulin receptor substrate-1 affecting association with the tyrosine phosphatase 2C and phosphatidylinositol 3-kinase.

  1995cited by this paper
• Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells.

  1995cited by this paper
• lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin

  1994cited by this paper
• Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: interaction with GH-releasing hormone, thyrotropin-releasing hormone, and octreotide.

  1994cited by this paper
• Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes.

  1993cited by this paper
• Somatostatin analogs for diagnosis and treatment of cancer.

  1993cited by this paper
• Interactions of the p107 and Rb proteins with E2F during the cell proliferation response.

  1993cited by this paper
• Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes.

  1993cited by this paper
• FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line.

  1993cited by this paper
• Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle

  1992cited by this paper
• Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.

  1992cited by this paper

• A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors

  2025cites this paper
• Somatostatin receptors in GtoPdb v.2025.3

  2025cites this paper
• Aggressive pituitary tumors and carcinomas: medical treatment beyond temozolomide.

  2024cites this paper
• Immunohistochemical Analyses of Mammalian Target of Rapamycin (mTOR) Expression in Pituitary Neuroendocrine Tumors (PitNETs): mTOR as a Therapeutic Target for Functional PitNETs

  2023cites this paper
• Somatostatin receptors in GtoPdb v.2023.1

  2023cites this paper
• Identification of cholesterol metabolism-related subtypes in nonfunctioning pituitary neuroendocrine tumors and analysis of immune infiltration

  2023cites this paper
• Pituitary Tumorigenesis—Implications for Management

  2023cites this paper
• Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways

  2023cites this paper
• Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine

  2022cites this paper
• DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells

  2022cites this paper
• A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer

  2022cites this paper
• High-risk pituitary adenomas and strategies for predicting response to treatment

  2022cites this paper
• PI3K inhibition by BKM120 results in anti-proliferative effects on corticotroph tumor cells

  2022cites this paper
• Direct effects of octreotide on osteoblast cell proliferation and function

  2022cites this paper
• TGF‐β1/Smad2/3 signaling pathway modulates octreotide antisecretory and antiproliferative effects in pituitary somatotroph tumor cells

  2021cites this paper
• Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors

  2021cites this paper
• Eukaryotic translation initiation factors as promising targets in cancer therapy

  2020cites this paper
• Somatostatin receptor expression and mTOR pathway activation in glioneuronal tumours of childhood.

  2020cites this paper
• Contemporary Management of Clinically Non-functioning Pituitary Adenomas: A Clinical Review

  2020cites this paper
• Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling.

  2020cites this paper
• Systemic treatment for lung carcinoids: from bench to bedside

  2019cites this paper
• Emerging and Novel Treatments for Pituitary Tumors

  2019cites this paper
• Aggressive Prolactin-Secreting Pituitary Adenomas and Carcinomas

  2019cites this paper
• Glioneuronal tumours in childhood Clinical picture , long-term outcome and possible new treatments

  2019cites this paper
• Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms

  2019cites this paper
• Pituitary carcinomas: Rare and challenging

  2019cites this paper
• Somatostatin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors

  2019cites this paper
• The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma

  2019cites this paper
• Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models

  2019cites this paper
• DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma.

  2019cites this paper
• Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas

  2019cites this paper
• In vitro anti-echinococcal activity of octreotide: additive effect of metformin linked to autophagy.

  2019cites this paper
• Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases

  2018cites this paper
• PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line

  2018cites this paper
• European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.

  2018cites this paper
• Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma)

  2018cites this paper
• Molecular challenges of neuroendocrine tumors ( Review )

  2018cites this paper
• Aggressive and malignant pituitary tumours: state-of-the-art.

  2018cites this paper
• Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting

  2018cites this paper
• Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options

  2018cites this paper
• Molecular challenges of neuroendocrine tumors.

  2017cites this paper
• Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro

  2017cites this paper
• Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies.

  2017cites this paper
• MANAGEMENT OF ENDOCRINE DISEASE: Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas.

  2017cites this paper
• Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors

  2017cites this paper
• Effects of metformin on cell growth and AMPK activity in pituitary adenoma cell cultures, focusing on the interaction with adenylyl cyclase activating signals.

  2017cites this paper
• Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro.

  2017influential citation
• Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas

  2017cites this paper
• Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma

  2017cites this paper
• Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?

  2017cites this paper
• Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas.

  2016cites this paper
• Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors

  2016cites this paper
• FGFR4 Polymorphism as Molecular Determinant of the Efficacy of mTOR Inhibitors In GH-Secreting Pituitary Adenomas.

  2016cites this paper
• Régulation de l'agressivité tumorale mammaire par la protéine tyrosine phosphatase PTPL1/PTPN13

  2016cites this paper
• The PI3K/Akt Pathway in Tumors of Endocrine Tissues

  2016cites this paper
• Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.

  2015cites this paper
• Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas

  2015cites this paper
• Capítulo 11 – Manejo de los tumores hipofisarios agresivos

  2015cites this paper
• Clinicopathological Correlates of Pituitary Adenoma

  2015cites this paper
• Role of AMP‐Activated Protein Kinase Activators in Antiproliferative Multi‐Drug Pituitary Tumour Therapies: Effects of Combined Treatments with Compounds Affecting the mTOR‐p70S6 Kinase Axis in Cultured Pituitary Tumour Cells

  2015cites this paper
• Capítulo 1 – Ciclo celular y tumorogénesis hipofisaria

  2015cites this paper
• Post-surgical management of non-functioning pituitary adenoma.

  2015cites this paper
• Combination of mTOR Inhibitors Augments Potency while Activating PI3K Signaling in Pituitary Tumors

  2015cites this paper
• Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells

  2015cites this paper
• The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly

  2015cites this paper
• Molecular genetic advances in pituitary tumor development

  2015cites this paper
• Adénomes hypophysaires gonadotropes

  2014cites this paper
• Treatment of Pituitary Carcinomas and Atypical Pituitary Adenomas: A Review

  2014cites this paper
• IGF1 induces cell proliferation in human pituitary tumors - functional blockade of IGF1 receptor as a novel therapeutic approach in non-functioning tumors.

  2014influential citation
• Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.

  2014cites this paper
• Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors

  2014cites this paper
• The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas.

  2014influential citation
• Rapamycin‐loaded poly(ε‐caprolactone)‐poly(ethylene glycol)‐poly(ε‐caprolactone) nanoparticles: preparation, characterization and potential application in corneal transplantation

  2014cites this paper
• Molecular basis of pharmacological therapy in Cushing’s disease

  2014cites this paper
• Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy.

  2014cites this paper
• Somatostatin receptor sst2 reduces Akt activity and aggravates hypoxic/ischemic death in cerebral cortical neurons.

  2014cites this paper
• Regulation of pituitary growth hormone synthesis by NAD+ dependent deacetylase Sirt1

  2014cites this paper
• Somatostatin system: molecular mechanisms regulating anterior pituitary hormones.

  2014influential citation
• MANAGEMENT OF ENDOCRINE DISEASE Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies

  2014cites this paper
• Differential molecular mechanism of docetaxel–octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells

  2013cites this paper
• The place of medical treatment of acromegaly: current status and perspectives

  2013cites this paper
• Effects of AMPK activation and combined treatment with AMPK activators and somatostatin on hormone secretion and cell growth in cultured GH-secreting pituitary tumor cells.

  2013influential citation
• mTOR is Frequently Active in GH-Secreting Pituitary Adenomas without Influencing their Morphopathological Features

  2013cites this paper
• Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.

  2013cites this paper
• Somatostatin receptors: from signaling to clinical practice.

  2013influential citation
• Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm

  2013cites this paper
• Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.

  2012cites this paper
• Antitumor effects of somatostatin analogs in neuroendocrine tumors.

  2012cites this paper
• Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.

  2012influential citation
• Treatment of nonfunctioning pituitary adenomas: what were the contributions of the last 10 years? A critical view.

  2012cites this paper
• Attenuation of the Retinoblastoma Pathway in Pancreatic Neuroendocrine Tumors Due to Increased Cdk4/Cdk6

  2012cites this paper
• Cancer Therapy : Preclinical Attenuation of the Retinoblastoma Pathway in Pancreatic Neuroendocrine Tumors Due to Increased Cdk 4 / Cdk 6

  2012cites this paper
• Contribution of angiogenesis and rationale for use of targeted therapies in digestive neuroendocrine tumours

  2012cites this paper
• New targeted therapies in pituitary carcinoma resistant to temozolomide

  2012influential citation
• PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas

  2012cites this paper
• Physiopathology of somatolactotroph cells: from transduction mechanisms to cotargeting therapy

  2011cites this paper
• Levels of p27 Sensitize to Dual PI3K/mTOR Inhibition

  2011cites this paper
• Levels of p 27 Sensitize to Dual PI 3 K / mTOR Inhibition

  2011cites this paper
• The biological hallmarks of ileal carcinoids

  2011cites this paper